Frontlight ResearchEarly access
Lung cancer trials in United States
900 trials · From ClinicalTrials.gov, checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Where
- Athens, Baltimore, Fairfax, Glendale, Houston, Louisville, Pinehurst, Washington D.C.
- Age
- 18 years and over
- People
- 128 worldwide
- Run by
- Teligene US
See details and how to joinNCT05168566 - Phase 1/2Taking peopleStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Where
- Aurora, Boston, Cleveland, Columbus, Detroit, Duluth, East Brunswick, Easton, Fort Wayne, Fullerton, Hinsdale, Houston, Indianapolis, Jacksonville, Leesburg, Lone Tree, Lubbock, Olympia, Orange City, Overland Park, Oxnard, Phoenix, Rochester, Salt Lake City, Santa Monica, Shirley, Tacoma
- Age
- 18 years and over
- People
- 252 worldwide
- Run by
- AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00 - Phase 3Taking peopleA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Where
- Annapolis, Arlington Heights, Birmingham, Boston, Cedar Rapids, Chicago, Clearwater, Columbia, Cooperstown, Dallas, Denver, Detroit, Dyer, Edgewood, Fenton, Fort Wayne, Fullerton, Galveston, Greenville, Jacksonville, Laredo, Loma Linda, Long Beach, Louisville, Marietta, Miami, Nashville, Newark, Ocala, Orange City, Owensboro, Paducah, Palm Bay, Plantation, San Antonio, Schenectady, Shreveport, Springdale, Springfield, St. Petersburg, Tamarac, Tampa, Tyler, White Plains, York
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00 - Phase 2Taking peopleA Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
- Where
- Boston, Cleveland, Columbia, Detroit, Fairfax, Fort Wayne, Gainesville, Houston, Lexington, New Haven, Ocala, Tampa
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- AbbVie
See details and how to joinNCT07155174 · EU 2024-517490-24-00 - No phaseTaking peopleTailored Patient Navigation to Improve the Uptake of Lung Cancer Screening in Tribal Communities in Western Washington State, SACRED LUNGS Trial
- Where
- Auburn, Shelton
- Age
- 18 years and over
- People
- 237
- Run by
- Fred Hutchinson Cancer Center
See details and how to joinNCT07176000 - Phase 1Taking peopleDBC-664 in Adult Patients With Solid Tumors
- Where
- Denver, East Brunswick, Grand Rapids, Lake Success, Nashville, San Antonio, St Louis
- Age
- 18 years and over
- People
- 210
- Run by
- Duboce Biopharmaceuticals, Inc.
See details and how to joinNCT07705035 - Phase 1/2Taking peoplePhase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Where
- Boston, Nashville, Scottsdale
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Strand Therapeutics Inc.
See details and how to joinNCT07751042 - Phase 1Taking peopleImpact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib
- Where
- Chicago
- Age
- 18 years and over
- People
- 30
- Run by
- University of Chicago
See details and how to joinNCT07782359 - No phaseNot yet taking people in United StatesUsing an Artificial Intelligence Software Tool (iSeg) During Radiation Treatment Planning for Patients With Lung Tumors
- Where
- Chicago
- Age
- 18 years and over
- People
- 34
- Run by
- Northwestern University
See details and how to joinNCT07898241 - Phase 1/2Taking peopleStudy of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
- Where
- Pittsburgh
- Age
- 18 years and over
- People
- 30
- Run by
- Olivera Finn
See details and how to joinNCT01720836 - No phaseTaking peopleSolid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Where
- Boston, Columbus, Duarte, Gilbert, Houston, Jacksonville, La Jolla, Nashville, New York, Palo Alto, Phoenix, Rochester, Santa Monica, Seattle, St Louis, Tampa
- Age
- 18 years and over
- People
- 500
- Run by
- A2 Biotherapeutics Inc.
See details and how to joinNCT04981119 - No phaseTaking peoplePreliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial
- Where
- Boston
- Age
- 18 years and over
- People
- 30
- Run by
- Dana-Farber Cancer Institute
See details and how to joinNCT06026111 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Baltimore, Buffalo, Chicago, Duarte, Houston, Kissimmee, Nashville, New Haven, New York, Rockville, Saint Louis Park, Saint Paul, Seattle, St Louis
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 1Taking peopleA Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Where
- Boston, Durham, Fairfax, Houston, Nashville, New York, Orlando, San Antonio, St Louis, Tampa
- Age
- 18 years and over
- People
- 448
- Run by
- Alterome Therapeutics, Inc.
See details and how to joinNCT06835569 - No phaseTaking peopleNew York Better Breathing Study
- Where
- Buffalo
- Age
- 18 years and over
- People
- 100
- Run by
- Roswell Park Cancer Institute
See details and how to joinNCT06869447 - Phase 2Taking peopleTrial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
- Where
- Birmingham, Durham, Los Angeles, Mineola, New York
- Age
- 18 years and over
- People
- 131 worldwide
- Run by
- CatalYm GmbH
See details and how to joinNCT07246863 · EU 2024-516794-70-00 - Phase 2Taking peopleSMARCA4/2 Inhibitor for POU2F3-Positive SCLC
- Where
- Boston
- Age
- 18 years and over
- People
- 20
- Run by
- Dana-Farber Cancer Institute
See details and how to joinNCT07551635 - Phase 2/3Not yet taking people in United StatesGlobal, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
- Where
- Kingwood, Port Saint Lucie
- Age
- 18 years to 80 years
- People
- 512 worldwide
- Run by
- Multitude Therapeutics Inc.
See details and how to joinNCT07718737 - Phase 1/2Taking peopleA Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
- Where
- Fairfax, Lake Success
- Age
- 18 years and over
- People
- 392 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07730021 · EU 2026-525938-31-00 - No phaseTaking peopleVeterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
- Where
- Ann Arbor, Baltimore, Bay Pines, Boston, Cleveland, Durham, Hines, Houston, Indianapolis, Long Beach, Miami, Milwaukee, Minneapolis, Philadelphia, Pittsburgh, Richmond, West Los Angeles
- Age
- 18 years and over
- People
- 670
- Run by
- VA Office of Research and Development
See details and how to joinNCT02984761 - No phaseTaking peopleQuality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer
- Where
- Buffalo
- Age
- 18 years and over
- People
- 150
- Run by
- Roswell Park Cancer Institute
See details and how to joinNCT05292521 - Phase 3Taking peopleStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Where
- Anchorage, Atlanta, Bay Pines, Bend, Boca Raton, Boston, Canton, Fort Lauderdale, Fountain Valley, Hinsdale, Honolulu, Houston, Kalispell, Kingwood, Los Angeles, Orange City, Pinehurst, Plantation, Reno, Rochester, Santa Rosa, Spokane, Westbury, Weston, Wilson
- Age
- 18 years and over
- People
- 686 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00 - Phase 1Taking peopleA Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
- Where
- Fairfax, New York
- Age
- 18 years and over
- People
- 140 worldwide
- Run by
- Dizal Pharmaceuticals
See details and how to joinNCT06905197 - Phase 1/2Taking peopleStudy to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- Where
- Boston, Chapel Hill, Chicago, Denver, Fairfax, Houston, Indianapolis, Iowa City, Irving, Jacksonville, New York, Omaha, Rochester, Salt Lake City, Scottsdale, Washington D.C.
- Age
- 18 years and over
- People
- 183
- Run by
- Tango Therapeutics, Inc.
See details and how to joinNCT06922591 - Phase 1Taking peopleA Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
- Where
- Ann Arbor, Atlanta, Dallas, Edwards, Fairfax, Fullerton, Hackensack, Orange, Peoria, St Louis
- Age
- 18 years and over
- People
- 40 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07140016 · EU 2025-522398-12-00